What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?)

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 87-97

  Low, Donald E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

lactams; Antimicrobial resistance; Community acquired pneumonia; Fluoroquinolones; Macrolides; Pollyanna phenomenon; Resistance paradox; Streptococcus pneumoniae

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG USE; HUMAN; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84873561593     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.013     Document Type: Review

References (36)

1. File T.M., Tan J.S., Boex J.R. The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective. Clin Infect Dis 2006, 42:798-800.
2. Jones R.N., Sader H.S., Mendes R.E., et al. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2012, 10.1016/j.diagmicrobio.2012.08.024.
3. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. CLSI document M100-S18 2008, Clinical and Laboratory Standards Institute, Wayne (PA).
4. Pallares R., Linares J., Vadillo M., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480. [see comments] [published erratum appears in N Engl J Med 1995;333(24):1655].
5. Yu V.L., Chiou C.C., Feldman C., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37:230-237.
6. Song J.H., Jung S.I., Ki H.K., et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004, 38:1570-1578.
7. Centers for Disease Control and Prevention (CDC) Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae-United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2008, 57:1353-1355.
8. Rosen J., Beekmann S., Polgreen P., et al. Barriers to intravenous penicillin use for treatment of nonmeningitis pneumococcal disease. J Clin Microbiol 2010, 48:3372-3374.
9. Klugman K.P., Lonks J.R. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 2005, 11:802-807.
10. Daneman N., McGeer A., Green K., et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006, 43:432-438.
11. Farrell D.J., Couturier C., Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Int J Antimicrob Agents 2008, 31:245-249.
12. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
13. Marchant C.D., Carlin S.A., Johnson C.E., et al. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the " Pollyanna phenomenon" . J Pediatr 1992, 120:72-77.
14. Levy M.L., Le J.I., Woodhead M.A., et al. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J 2010, 19:21-27.
15. Tilghman R.C., Finland M. Clinical significance of bacteremia in pneumococcic pneumonia. Arch Intern Med 1937, 59:602-619.
16. Evans G.M., Gaisford W.F. Treatment of pneumonia with 2-(p-aminobenzenesulphonamido) pyridine. Lancet 1938, 2:14-19.
17. Peterson L.R. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?. Clin Infect Dis 2006, 42:224-233.
18. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964, 60:759-770.
19. Metlay J.P., Singer D.E. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect 2002, 8(Suppl 2):1-11.
20. Moore H.F., Chesney A.N. A study of ethylhydrocuprein (Optochin) in the treatment of acute lobar pneumonia. Arch Intern Med 1917, 19:611-682.
21. Tleyjeh I.M., Tlaygeh H.M., Hejal R., et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006, 42:788-797.
22. Feikin D.R., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000, 90:223-229.
23. Turett G.S., Blum S., Fazal B.A., et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999, 29:321-327.
24. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 35:556-564.
25. Chen D., McGeer A., de Azavedo J.C., et al. The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999, 341:233-239.
26. Patel S.N., McGeer A., Melano R., et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother 2011, 55:3703-3708.
27. Davidson R., Cavalcanti R., Brunton J.L., et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002, 346:747-750.
28. Anderson K.B., Tan J.S., File T.M., et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003, 37:376-381.
29. Weinstein M.P., Klugman K.P., Jones R.N. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009, 48:1596-1600.
30. Eliakim-Raz N., Robenshtok E., Shefet D., et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012, 9:CD004418.
31. Mills G.D., Oehley M.R., Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005, 330:456.
32. Bebear C., Pereyre S., Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011, 6:423-431.
33. Yamada M., Buller R., Bledsoe S., et al. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012, 31:409-411.
34. Centers for Disease Control and Prevention Health hazards associated with laundry detergent pods-United States, May-June 2012. MMWR Morb Mortal Wkly Rep 2012, 61:825-829.
35. Watanabe A., Yanagihara K., Matsumoto T., et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens' antibacterial susceptibility. J Infect Chemother 2012, 18(5):609-620.
36. Daneman N., Low D.E., McGeer A., et al. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis 2008, 46:1131-1138.